+Compare
GLUE
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
301.43M

GLUE Monte Rosa Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for GLUE with price predictions
08:00 PM EDT Sep 26, 2023

GLUE's RSI Indicator ascends from oversold territory

The RSI Indicator for GLUE moved out of oversold territory on August 28, 2023. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In of the 10 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 29 cases where GLUE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GLUE just turned positive on September 14, 2023. Looking at past instances where GLUE's MACD turned positive, the stock continued to rise in of 21 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLUE advanced for three days, in of 136 cases, the price rose further within the following month. The odds of a continued upward trend are .

GLUE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 27, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on GLUE as a result. In of 42 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for GLUE entered a downward trend on September 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.306) is normal, around the industry mean (22.662). P/E Ratio (1.818) is within average values for comparable stocks, (131.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.103). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (306.452).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GLUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 407B. NVO holds the highest valuation in this group at 407B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 17%, and the average quarterly price growth was 37%. SYBX experienced the highest price growth at 816%, while BCLI experienced the biggest fall at -78%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 126% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

GLUE is expected to report earnings to -71 cents per share on November 09

Monte Rosa Therapeutics GLUE Stock Earnings Reports
Q3'23
Est.
$-0.72
Q2'23
Missed
by $0.01
Q1'23
Beat
by $0.03
Q4'22
Missed
by $0.01
Q3'22
Beat
by $0.02
The last earnings report on August 10 showed earnings per share of -70 cents, missing the estimate of -69 cents. With 262.44K shares outstanding, the current market capitalization sits at 301.43M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
645 Summer Street
Phone
+1 617 949-2643
Employees
123
Web
https://www.monterosatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMGYX22.610.26
+1.16%
Columbia Select Mid Cap Gro Fd I3
RYNHX86.080.75
+0.88%
Rydex Nova H
PFGRX27.370.21
+0.77%
Pioneer Fundamental Growth R
NCGFX54.390.36
+0.67%
New Covenant Growth
MYITX6.750.04
+0.60%
MainStay WMC Intl Research Eq A

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with MDGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
-14.95%
MDGL - GLUE
47%
Loosely correlated
+0.14%
KNTE - GLUE
43%
Loosely correlated
-6.12%
ERAS - GLUE
43%
Loosely correlated
-6.91%
IMGN - GLUE
42%
Loosely correlated
+3.90%
LYEL - GLUE
41%
Loosely correlated
-0.63%
More